A- A A+

Syringe Service Program Perspectives on Barriers, Readiness, and Programmatic Needs to Support Rollout of the COVID-19 Vaccine. 

Corcorran MA, Austin EJ, Behrends CN, Briggs ES, Frost MC, Juarez AM, Frank ND, Healy E, Prohaska SM, LaKosky PA, Kapadia SN, Perlman DC, Schackman BR, Des Jarlais DC, Williams EC, Glick SN. 

J Addict Med. 2023 Jan-Feb 01;17(1):e36-e41. doi: 10.1097/ADM.0000000000001036. Epub 2022 Aug 2. PMID: 35916422; PMCID: PMC9892351.


The next generation of coronavirus vaccines: a graphical guide. 

Callaway E. 

Nature. 2023 Feb;614(7946):22-25. doi: 10.1038/d41586-023-00220-z. PMID: 36726000.


Predictors of COVID-19 vaccine uptake among people who inject drugs. 

Strathdee SA, Abramovitz D, Vera CF, Artamonova I, Patterson TL, Smith DM, Chaillon A, Bazzi AR. 

Vaccine. 2023 Jan 23:S0264-410X(23)00063-4. doi: 10.1016/j.vaccine.2023.01.042. Epub ahead of print. PMID: 36697311; PMCID: PMC9868393.


USA: FDA-Berater für jährliche COVID-19-Impfungen

Silver Spring/Maryland – Die US-Arzneimittelbehörde FDA hat auf einer Beratertagung Pläne zur Vereinheit­lichung der COVID-19-Impfungen vorgestellt. Künftig sollen alle Impfungen mit kombinierten Impfstoffen er­folgen, deren Inhalt jährlich festgelegt werden soll. Die externen Experten haben den Plänen überwiegend zugestimmt. (aerzteblatt.de, 27.01.2023)


WHO. COVID-19 Vaccine Delivery Partnership

Global equitable access to a COVID-19 vaccine, particularly for health workers and other most-at-risk populations, is the only way to mitigate the public health and economic impact of the pandemic. More than 12 billion vaccine doses have been administered globally, and now, with a predictable supply of COVID-19 vaccines, more must be done to deliver them to those most in need. (WHO, Genf, aufgerufen am 06.01.2023)


Vaccine Perceptions and Willingness to Receive COVID-19 Vaccination: Opportunities to Strengthen Public Health Responses and COVID-19 Services for People Who Use Drugs. 

Jordan AE, Izar R, Nicolas R, Beharie N, Harocopos A. Understanding 

Vaccines (Basel). 2022 Nov 29;10(12):2044. doi: 10.3390/vaccines10122044. PMID: 36560454; PMCID: PMC9784169.


Lisbon Addictions 2022. Will they accept the vaccine? A 2021 COVID-19 survey among 477 people who use drugs in Norway

To combat the COVID-19 pandemic, adherence to COVID-19 recommendations and vaccination against COVID-19 is important. Among people who use drugs (PWUD), little is known regarding compliance with COVID-19 recommendations, COVID-19 testing and attitudes towards COVID-19 vaccination. In a sample of PWUD, we examined these issues. (Gabrielle K. Welle-Strand, Lisbon Addictions 2022, Präsentation)


Global state of education-related inequality in COVID-19 vaccine coverage, structural barriers, vaccine hesitancy, and vaccine refusal: findings from the Global COVID-19 Trends and Impact Survey

Bergen, Nicole et al.

The Lancet Global Health, Volume 0, Issue 0 


Lessons from COVID-19 to increase opioid vaccine acceptance. 

Damiescu R, Banerjee M, Paul NW, Efferth T. 

Trends Pharmacol Sci. 2022 Sep 7:S0165-6147(22)00196-1. doi: 10.1016/j.tips.2022.08.010. Epub ahead of print. PMID: 36123169; PMCID: PMC9448697.


Use of COVID-19 testing in the first year of the COVID-19 pandemic among cohorts of people at the intersection of drug use and HIV. 

Gorbach PM, Rosen AD, Moore R, Shoptaw S, Mustanski B, Mehta SH, Kirk GD, Baum MK, Milloy MJ, Hayashi K, DeBeck K, Kipke M, Lai S, Siminski S, Javanbakht M. 

Drug Alcohol Depend. 2022 Sep 6:109622. doi: 10.1016/j.drugalcdep.2022.109622. Epub ahead of print. PMID: 36123252; PMCID: PMC9444299.


Neue STIKO-Empfehlungen: Auffrischung der COVID-19-Impfung

Dtsch Arztebl 2022; 119(35-36): A-1461

Kling, Kerstin; Piechotta, Vanessa


Kanada. Lower vaccination rates among people who use drugs could lead to serious outcomes from COVID-19

As many jurisdictions in Canada begin to ease public health measures intended to limit serious cases and fatalities caused by COVID-19, new research from the BC Centre on Substance Use (BCCSU) and the University of British Columbia (UBC) suggests many people remain at risk of serious disease.

The Government of Canada, through its COVID-19 Immunity Task Force study provided approximately $770,000 in funding to support a study investigating vaccine confidence uptake among people who use drugs in Vancouver’s Downtown Eastside and Downtown South neighbourhoods. Preliminary findings from this study found that just under two-thirds of the group had received at least two doses of a vaccine against COVID-19. (British Columbia Centre on Substance Use, Kanada, 06.04.2022)


Motivational Interviewing Strategies for Addressing COVID-19 Vaccine Hesitancy. 

Boness CL, Nelson M, Douaihy AB. 

J Am Board Fam Med. 2022 Mar-Apr;35(2):420-426. doi: 10.3122/jabfm.2022.02.210327. PMID: 35379731.


COVID-19 vaccination coverage, vaccine hesitancy and opioid use disorder: Correspondence. 

Mungmunpuntipantip R, Wiwanitkit V. 

Drug Alcohol Rev. 2022 Jul 14:10.1111/dar.13514. doi: 10.1111/dar.13514. Epub ahead of print. PMID: 35836384; PMCID: PMC9349915.


Ministerium löscht Tweet zu Coronaimpfungen: Was steckt dahinter?

Berlin – Die angebliche Zahl schwerer Nebenwirkungen der Coronaimpfungen sind seit Monaten ein Zankapfel in Politik und Gesellschaft. Dabei gibt es schon seit Beginn der Impfkampagne Daten des Paul-Ehrlich-Instituts (PEI).

Jüngst hat aber selbst das Bundesgesundheitsministerium (BMG) irreführende Informationen verbreitet – und musste zurückrudern. In einem Tweet hatte das Ministerium am 20. Juli geschrieben: „Eine von 5.000 Personen ist von einer schweren Nebenwirkung nach einer COVID-19-Impfung betroffen“. Der Tweet wurde mittlerweile gelöscht, denn die Bewertung ist falsch. (aerzteblatt.de, 22.07.2022)


WHO. Global COVID-19 Vaccination Strategy in a Changing World: July 2022 update

This strategy brief outlines updated goals, steps, targets, and operational priorities to guide countries, policy makers, civil society, manufacturers, and international organizations in their ongoing efforts through 2022. The goals are to sustain and enhance momentum to reduce mortality and morbidity, protect health systems, and resume socio-economic activities with existing vaccines, and to accelerate the development and access to improved vaccine products.

Towards the end of 2022, as more scientific uncertainties get resolved and more data becomes available, WHO will embark on a consultative process to develop a global Covid-19 vaccination strategy for 2023 and beyond. (WHO, Genf, 22.07.2022)


Who to vaccinate first? A peek at decision-making in a pandemic

Faced with the challenge of advising the World Health Organization on who should be the first to receive COVID-19 vaccines, an advisory group used an approach it hadn’t tried before. (Nature, USA, 12.07.2022)


The global impact of disproportionate vaccination coverage on COVID-19 mortality. 

Wells CR, Galvani AP. 

Lancet Infect Dis. 2022 Jun 23:S1473-3099(22)00417-0. doi: 10.1016/S1473-3099(22)00417-0. Epub ahead of print. PMID: 35753320; PMCID: PMC9225109.


Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

Watson, Oliver J et al.

The Lancet Infectious Diseases, Volume 0, Issue 0


Studie: Impfungen gegen COVID-19 haben weltweit fast 20 Millionen Todesfälle verhindert

London – Im ersten Jahr der Pandemie sind weltweit 8,33 Milliarden Impfstoffdosen an 4,36 Milliarden Menschen verabreicht worden. Dies könnte nach Berechnungen in Lancet Infectious Diseases (2022; DOI: 10.1016/S1473-3099(22)00320-6) mehr als 40 % der Übersterblichkeit durch COVID-19 verhindert und 19,8 Millionen Menschen das Leben gerettet haben. (aerzteblatt.de, 24.06.2022)


Ungeimpfte mit höchsten COVID-19-Hospitalisierungsinzidenzen

Berlin – Die höchsten Inzidenzen der hospitalisierten COVID-19-Fälle liegen in allen Altersgruppen in der ungeimpften Bevölkerung vor. Dies geht aus dem heute veröffentlichten Monatsbericht des Robert-Koch-Institutes (RKI) zum COVID-19-Impfgeschehens in Deutschland hervor. (aerzteblatt.de, 07.07.2022)


Uptake of COVID-19 vaccination among people who inject drugs. 

Iversen J, Wand H, Kemp R, Bevan J, Briggs M, Patten K, Heard S, Maher L. 

Harm Reduct J. 2022 Jun 3;19(1):59. doi: 10.1186/s12954-022-00643-3. PMID: 35655217; PMCID: PMC9162792.


Willingness to receive an annual COVID-19 booster vaccine in the German-speaking D-A-CH region in Europe: A cross-sectional study

Weitzer, Jakob et al.

The Lancet Regional Health – Europe, Volume 18, 100414 


Post-Vac-Syndrom: Seltene Folgen nach Impfung

Dtsch Arztebl 2022; 119(19): A-862 / B-714

Gießelmann, Kathrin; Martin, Mirjam


Einstellungen zur Corona-Schutzimpfung

Ergebnisse einer deutschlandweiten Befragung der Allgemeinbevölkerung sowie des medizinischen und pflegerischen Personals

Attitudes toward Corona vaccination—findings of a nationwide survey of the general population and of medical and nursing staff in Germany

Dtsch Arztebl 2022; 18. Mai 2022; DOI: 10.3238/arztebl.m2022.0206; ONLINE first

Muschalik, Carolin; Orth, Boris; Merkel, Christina; von Rüden, Ursula; De Bock, Freia


Social media and attitudes towards a COVID-19 vaccination: A systematic review of the literature

Cascini, Fidelia et al.

eClinicalMedicine, Volume 0, Issue 0, 101454 


Vaccination and Communicable Disease Testing Services' Integration Within a Syringe Services Program: A Program Brief. 

Heidari O, Meyer D, O'Conor KJ, Cargill V, Patch M, Farley JE. COVID-19 

J Assoc Nurses AIDS Care. 2022 May-Jun 01;33(3):348-352. doi: 10.1097/JNC.0000000000000322. Epub 2022 Jan 12. PMID: 35025822.


Belegt die Charité-Studie wirklich 40-mal so viele Impfnebenwirkungen?

Ein Stiftungsprofessor für Anthroposophische Medizin berichtet neue Daten – und Journalisten verbreiten seine Ergebnisse kritiklos. Was ist dran an der Sache? (Spektrum.de, 05.05.2022)


Kein Nachweis für vermehrte Impfnebenwirkungen 

Einer Studie der Berliner Charité zufolge soll es 40 Mal häufiger zu schweren Impfnebenwirkungen bei Corona-Vakzinen kommen als vom PEI angegeben. Doch an der Methodik und dem Ergebnis gibt es starke Zweifel. (Tagesschau, faktenfinder, 10.05.2022)


ImpfSurv. Sicherheitsprofil von COVID-19 Impfstoffen

Studienleitung: Prof. Dr. Harald Matthes 

Klinik, Institut: Charité - Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie (einschl. Arbeitsbereich Ernährungsmedizin) CBF 

Status: Teilnehmende gesucht, Stand: 07.05.2022